资讯|新利18手机|病例

搜索

首页 18luck西部 专业文章 医学进展 签约作者 病例中心 快问诊所 新利网官方网站 医学考试 在线题库 医学会议

您所在的位置:首页>血液科专家课件> Myelodysplastic syndrome

Myelodysplastic syndrome

2013-10-24 21:20 阅读:1452 来源:爱爱医 责任编辑: zhima880127
[导读]《 Myelodysplasticsyndrome 》内容预览: (点击下图可阅读全部内容) It is a term for a heterogeneous collection of haemopoietic stem cell disorders affecting older **s. There is underlying ineffectiveness of haemopoiesis that results in

Myelodysplastic syndrome内容预览:

(点击下图可阅读全部内容)

It is a term for a heterogeneous collection of haemopoietic stem cell disorders affecting older adults.
There is underlying ineffectiveness of haemopoiesis that results in dysplasia of bone marrow precursors and pe**heral cytopenias.

Moderate anaemia is the most common clinical problem in MDS patients, but complete myeloid bone marrow failure also occurs leading to death from bleeding or infection.
Approximately half of the patients transform to AML.

Prognosis depends on the individual’s risk factors, with median survival ranging from 5.7 years in lower-risk group to 1.2 years or less in those with higher-risk MDS.
MDS is extremely difficult to treat. Most cases are resistant to current therapies, and the most potent anti-MDS treatments (transplantation and dose intensive chemotherapy) are often too toxic for the majority of patients.

The WHO proposed changes including reclassification of RAEB-t to AML and adding a subgroup called refractory cytopenias with dysplasia (RCD)

点击下载完整版:《Myelodysplastic syndrome


分享到:
版权声明:

本站所注明来源为"爱爱医"的文章,版权归作者与本站共同所有,非经授权不得转载。

本站所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,不希望被转载的媒体或个人可与我们

联系zlzs@120.net,我们将立即进行删除处理

意见反馈关于我们隐私保护版权声明友情链接联系我们

Copyright 2002-2024 Iiyi.Com All Rights Reserved

Baidu
map